TY - JOUR
T1 - Re-Irradiation of Recurrent Non-Small Cell Lung Cancer
AU - Hunter, Benjamin
AU - Crockett, Cathryn
AU - Faivre-Finn, Corinne
AU - Hiley, Crispin
AU - Salem, Ahmed
N1 - Funding Information:
Corinne Faivre-Finn is supported in part by the NIHR Manchester Biomedical Research Centre; Ahmed Salem is supported in part by the University of Manchester Presidential Research Fellowship for Clinicians and the Manchester Cancer Research Centre.
Publisher Copyright:
© 2020 Elsevier Inc.
PY - 2021/4
Y1 - 2021/4
N2 - Locoregional recurrence occurs in 10%-30% of non-small cell lung cancer (NSCLC) after treatment with definitive (chemo)radiotherapy. Re-irradiation is the main curative-intent treatment option for these patients; however, it represents a therapeutic challenge for thoracic radiation oncologists. Re-irradiation practices are variable worldwide with lack of agreement on the optimal dose or the cumulative maximum dose acceptable for critical organs. The role of re-irradiation in NSCLC is also not clearly defined in the era of immunotherapy. In this review, we will present published and on-going re-irradiation studies for recurrent NSCLC. We will appraise available evidence for critical organ dose constraints and provide a framework for future therapeutic approaches and trials.
AB - Locoregional recurrence occurs in 10%-30% of non-small cell lung cancer (NSCLC) after treatment with definitive (chemo)radiotherapy. Re-irradiation is the main curative-intent treatment option for these patients; however, it represents a therapeutic challenge for thoracic radiation oncologists. Re-irradiation practices are variable worldwide with lack of agreement on the optimal dose or the cumulative maximum dose acceptable for critical organs. The role of re-irradiation in NSCLC is also not clearly defined in the era of immunotherapy. In this review, we will present published and on-going re-irradiation studies for recurrent NSCLC. We will appraise available evidence for critical organ dose constraints and provide a framework for future therapeutic approaches and trials.
UR - http://www.scopus.com/inward/record.url?scp=85097782825&partnerID=8YFLogxK
U2 - 10.1016/j.semradonc.2020.11.009
DO - 10.1016/j.semradonc.2020.11.009
M3 - Review article
C2 - 33610269
AN - SCOPUS:85097782825
SN - 1053-4296
VL - 31
SP - 124
EP - 132
JO - Seminars in Radiation Oncology
JF - Seminars in Radiation Oncology
IS - 2
ER -
